이뮨온시아

424870KOSDAQ자연과학 및 공학 연구개발업

47.3 / 100

Reference Date: 2026-07-24

Financial Score18.5 / 40

News Sentiment15.8 / 25

Momentum3.0 / 20

Disclosure10.0 / 15

AI Analysis: the debt ratio is very low with excellent financial health but PBR raises overvaluation concerns. Plunged 18.7% over the past month, and news sentiment is neutral.

Company InformationBased on 2025 Annual Report

Business Overview

Imunovia specializes in developing antibody-based immunotherapy drugs, with key assets including Anti-PD-L1, Anti-CD47, and Anti-LAG-3 monoclonal antibodies. The company is conducting Phase 2 trials for IMC-001 in NK/T cell lymphoma and TMB-High solid tumors, aiming for domestic commercialization and the development of a global blockbuster drug.

Number of Employees

22people

Average Salary

103.5M KRW

Score Calculation Basis

Detailed Financial Score

PER

—Industry Average 43.644.0Point

PBR

9.41Industry Average 2.520.0Point

3.7x industry avg (risky)

ROE

-114.40Industry Average -32.093.5Point

3.6x industry avg (excellent)

Debt Ratio

1.66Industry Average 7.318.0Point

Half of industry avg (excellent)

Trend 3.0 / 10 points

Revenue Growth Rate

1.5 / 3

Operating Profit Growth Rate

1.5 / 3

ROE Trend

0.0 / 4

Detailed News Sentiment

3 totalPositive 1Neutral 1Negative 1Average Sentiment Score 63.3

Positive
中 면역관문억제제 또 국내 허가…국산 신약은 언제쯤
중국 기업의 면역관문억제제 국내 허가로 이뮨온시아와 같은 국내 바이오 기업의 경쟁력 강화 기대.
Negative
[BIO USA 2026] 이뮨온시아, 유증 후 LO 시험대서 조기철수
이뮨온시아의 대규모 유상증자 이후 바이오 USA 전시회에서 조기 철수 결정으로 인해 부정적 영향이 예상됩니다.
Neutral
기업 자금조달, 장기채 식고 단기시장 달아올랐다
전반적인 자금 조달 시장 동향 변화로 인해 이뮨온시아의 직접적인 영향은 제한적임을 나타냄.

Detailed Momentum

52-week position1.0Point

Near 52w low (1%, downtrend)

Current 2,930Won52-week high 15,38052-week low 2,760

1-month return0.0Point

1m -18.72% (strong drop)

Volume trend2.0Point

Volume decreasing

Detailed Disclosure

0 totalPositive 0Neutral 0Negative 0